Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Finch Therapeutics Group, Inc. (FNCH) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/07/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/28/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation"
05/18/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Lease Termination Agreement, by and between the Company and NRL WCS 200 Inner Belt Prop, LLC",
"Lease Termination Agreement, by and between the Company and NRL WCS 200 Inner Belt Prop, LLC"
05/11/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
05/10/2023 8-K Quarterly results
Docs: "Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates"
04/25/2023 8-K Quarterly results
04/18/2023 8-K Quarterly results
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates SOMERVILLE, Mass.,"
01/26/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
01/24/2023 8-K Quarterly results
01/06/2023 8-K Quarterly results
12/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CDI 38K 46K 115K 461K"
11/10/2022 8-K Quarterly results
Docs: "Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results • Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDI • Topline PRISM4 data anticipated in H1 2024 • Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 -- Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022. “We are pleased with the tremendous progress our team has made recently to advance the development of our lead program, with patient dosing now underway in our PRISM4 Phase 3..."
09/01/2022 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs...
Docs: "Investor Contact:"
08/25/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
04/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Media Contact:Jenna UrbanBerry & Company Public Relations 253-8881"
04/19/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs SOMERVILLE, Mass., April 19, 2022 -- Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 20%. This workforce reduction will allow the company to focus its financial resources on its recurrent C. difficile infection and autism spectrum disorder development programs, two wholly-owned programs that Finch is prioritizing, along with its Takeda-partnered work in inflammatory bowel disease . Finch plans to provide guidance on the expected extension of the Company’s cash runway as a result of the..."
03/31/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates SOMERVILLE, Mass., March 31, 2022 -- Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. “Finch achieved many significant milestones in 2021, including new clinical data readouts that support our lead product candidate, CP101, for the prevention of recurrent C. difficile infection and the advancement of our TAK-524 ulcerative colitis development program to Takeda for further development. Following a strategic review of our pipeline, we hav..."
03/01/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "2016 38K 46K 115K 461K"
11/10/2021 8-K Quarterly results
Docs: "Finch Therapeutics Group, Inc. Condensed Consolidated Statements of Operations FOR THE THREE MONTHSENDED SEPTEMBER 30, FOR THE NINE MONTHS",
"2016 38K 46K 115K 461K"
10/19/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "GF TAK-524 GF TAK-524 GF TAK-524 GF"
10/05/2021 8-K Quarterly results
09/13/2021 8-K Quarterly results
09/08/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
08/04/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
05/13/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy